ATE447560T1 - Amidderivat - Google Patents

Amidderivat

Info

Publication number
ATE447560T1
ATE447560T1 AT03738555T AT03738555T ATE447560T1 AT E447560 T1 ATE447560 T1 AT E447560T1 AT 03738555 T AT03738555 T AT 03738555T AT 03738555 T AT03738555 T AT 03738555T AT E447560 T1 ATE447560 T1 AT E447560T1
Authority
AT
Austria
Prior art keywords
amide derivative
het
halogen
present
formula
Prior art date
Application number
AT03738555T
Other languages
English (en)
Inventor
Tetsuo Asaki
Taisuke Hamamoto
Yukiteru Sugiyama
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30003594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE447560(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Application granted granted Critical
Publication of ATE447560T1 publication Critical patent/ATE447560T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03738555T 2002-06-28 2003-06-27 Amidderivat ATE447560T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2002189269 2002-06-28
JP2002305146 2002-10-18
JP2002377937 2002-12-26
PCT/JP2003/008192 WO2004002963A1 (ja) 2002-06-28 2003-06-27 アミド誘導体及び医薬

Publications (1)

Publication Number Publication Date
ATE447560T1 true ATE447560T1 (de) 2009-11-15

Family

ID=30003594

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03738555T ATE447560T1 (de) 2002-06-28 2003-06-27 Amidderivat

Country Status (15)

Country Link
US (1) US7494997B2 (de)
EP (1) EP1533304B1 (de)
JP (1) JP4552650B2 (de)
CN (1) CN100343237C (de)
AT (1) ATE447560T1 (de)
AU (1) AU2003246100A1 (de)
BR (1) BRPI0312288B8 (de)
CA (1) CA2490907C (de)
DE (1) DE60329918D1 (de)
DK (1) DK1533304T3 (de)
ES (1) ES2337995T3 (de)
MX (1) MXPA04012845A (de)
PT (1) PT1533304E (de)
RU (1) RU2315043C2 (de)
WO (1) WO2004002963A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7375175B2 (en) 2002-08-19 2008-05-20 National Starch And Chemical Investment Holding Corporation Dispersions containing living radicals
EP1585723A2 (de) * 2003-01-17 2005-10-19 Wisconsin Alumni Research Foundation Abgewandelte retinoidverbindungen und deren verwendung
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
AU2004246800B2 (en) * 2003-06-13 2008-12-04 Novartis Ag 2-aminopyrimidine derivatives as Raf kinase inhibitors
WO2005019238A1 (ja) * 2003-08-22 2005-03-03 Meiji Seika Kaisha, Ltd. 新規アザライド及びアザラクタム誘導体とその製造法
WO2005063709A1 (ja) * 2003-12-25 2005-07-14 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
AP2470A (en) * 2004-09-09 2012-09-17 Natco Pharma Ltd Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
EP2094682A2 (de) * 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl-verbindungen als cdk-hemmer zur behandlung von krebs, entzündungen und viralen infektionen
JP5559043B2 (ja) 2007-06-07 2014-07-23 イントラ−セルラー・セラピーズ・インコーポレイテッド 新規ヘテロ環化合物およびその使用
EP2166858A4 (de) 2007-06-07 2011-08-03 Intra Cellular Therapies Inc Neue heterocyclische verbindungen und ihre verwendung
EP2203436A1 (de) * 2007-09-17 2010-07-07 Neurosearch A/S Pyrazinderivate und ihre verwendung als kaliumkanalmodulatoren
CA2720164A1 (en) * 2008-03-31 2009-10-08 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
CA2753637A1 (en) 2009-03-06 2010-09-10 Novartis Ag Use of pyrimidylaminobenzamide derivatives for the treatment of disorders mediated by the leucine zipper- and sterile alpha motif-containing kinase (zak)
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
BR112012009094A8 (pt) 2009-10-23 2017-10-10 Novartis Ag método de tratamento de transtornos proliferativos e outras condições patológicas mediadas por bcr-abl, c-kit, ddr1,ddr2 ou atividade pdgf-r quinase
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
CN104244934A (zh) * 2012-03-14 2014-12-24 印第安纳大学研究及科技有限公司 用于治疗白血病的化合物和方法
PH12015501130B1 (en) 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
MX370588B (es) 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
US9975878B2 (en) 2013-11-21 2018-05-22 Ptc Therapeutics, Inc. Substituted triazine BMI-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
JP6778833B2 (ja) * 2017-01-20 2020-11-04 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． キナーゼ活性を抑制するための（ヘテロ）アリールアミド類化合物
CN108602800B (zh) * 2017-01-20 2019-08-27 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
AU2020232755A1 (en) * 2019-03-05 2021-11-04 Hongyi & Associates LLC. Compounds for treating neurodegenerative diseases and cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (de) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
ES2337995T3 (es) 2010-05-03
JP4552650B2 (ja) 2010-09-29
US20060014742A1 (en) 2006-01-19
WO2004002963A1 (ja) 2004-01-08
CN100343237C (zh) 2007-10-17
BRPI0312288B1 (pt) 2019-01-02
BR0312288A (pt) 2005-04-12
CA2490907A1 (en) 2004-01-08
JPWO2004002963A1 (ja) 2005-10-27
EP1533304A4 (de) 2006-10-18
PT1533304E (pt) 2010-02-08
AU2003246100A1 (en) 2004-01-19
BRPI0312288B8 (pt) 2021-05-25
DE60329918D1 (de) 2009-12-17
RU2315043C2 (ru) 2008-01-20
CA2490907C (en) 2010-08-24
DK1533304T3 (da) 2010-03-22
RU2005102098A (ru) 2005-09-20
CN1678590A (zh) 2005-10-05
MXPA04012845A (es) 2005-02-24
EP1533304A1 (de) 2005-05-25
EP1533304B1 (de) 2009-11-04
US7494997B2 (en) 2009-02-24

Similar Documents

Publication Publication Date Title
DK1533304T3 (da) Amidderivat
CY1120169T1 (el) Παραγωγο αμιδιου και φαρμακο
EA200200942A1 (ru) Фармацевтические композиции, содержащие производные 3-аминоазетидина, новые производные и способ их получения
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
FR2842804B1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
DE60316013D1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
MY150630A (en) Amide derivative and insecticide containing the same
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
WO2002074726A3 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EP2030971A4 (de) Schädlingsbekämpfungsmittel mit neuem pyridyl-methanamin-derivat oder salz daraus
MXPA05010521A (es) Inhibidores de cinasa de amida de bifenilcarboxilica p38.
DK1452528T3 (da) Xanthinoxidaserinhibitorer
ATE311367T1 (de) 5-substituierte alkylaminopyrazol-derivative als pestizide
DE60116589D1 (de) Fungizide Phenylamidinderivative
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
SE0103710D0 (sv) Compounds
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
DK0870763T3 (da) Kondenserede piperidinderivater som inhibitorer for syntese af nitrogenmonoxid
EP1357124A4 (de) Heterocyclische verbindungen und mittel, die die hirnfunktion verbessern und als wirkstoff diese verbindungen enthalten
TW200628153A (en) Novel compounds
BR0201569A (pt) 4-(2-piridil) piperizinas possuindo uma atividade agonista do receptor 5ht7
CY1110898T1 (el) Νεα παραγωγα πυριδινοκαρβοξυλικου οξεος ή αλατα αυτων
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1533304

Country of ref document: EP